TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03029949

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ACT with VR
Description: 6 weekly 120-minute group sessions of acceptance and commitment therapy with vestibular rehabilitation, and brief (approximately 15 minute) individual follow-up sessions at 1 and 3 months after the group treatment

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: self-treatment VR
Description: booklet written on vestibular rehabilitation for self-treatment

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: clinical management
Description: clinical management and pharmacotherapy as usual for chronic dizziness

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: clinical management
Description: clinical management and pharmacotherapy as usual for chronic dizziness
Study: NCT00456833

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RAD001

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: RAD001

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: erlotinib
Study: NCT01192711

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Diabetes Interactive Diary (DID)
Description: DID is both a CHO/insulin bolus calculator, an information technology and a telemedicine system based on the communication between health care professional (physician or dietitian) and patient by SMS messages.
Study: NCT03973203

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Niacin
Description: The dose for a slow-released form of niacin will be 750-1000 mg/day. The daily niacin dose, 250 mg/day, is gradually escalated by 250 mg/month so that the full dose is reached after 3 months. The intervention time with the full niacin dose is 1 and 7 months for controls and patients, respectively, and subsequently total intervention time 4 and 10 months, respectively. At the end of the study, the daily dose will be decreased by 250 mg/month rate.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Niacin
Description: The dose for a slow-released form of niacin will be 750-1000 mg/day. The daily niacin dose, 250 mg/day, is gradually escalated by 250 mg/month so that the full dose is reached after 3 months. The intervention time with the full niacin dose is 1 and 7 months for controls and patients, respectively, and subsequently total intervention time 4 and 10 months, respectively. At the end of the study, the daily dose will be decreased by 250 mg/month rate.
Study: NCT02077842

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Nasal Continuous Positive Airway Pressure
Description: Nasal continuous positive airway pressure at 10 cmH2O

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Low Flow Oxygen
Description: Low flow oxygen delivered via face mask at 8 litres per minute
Study: NCT01369407

Intervention type: OTHER
Intervention: No Intervention
Description: Not an interventional study
Study: NCT03936270

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palbociclib 125mg
Description: The Palbociclib capsules supplied for this study contains 75 mg, 100 mg or 125 mg of Palbociclib. It must be taken orally 125 mg once daily for 21 consecutive days followed by 7 days off treatment (Schedule 3/1) to comprise a complete cycle of 28 days.
Study: NCT04341857

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PD-1 Monoclonal Antibody(Sintilimab)
Description: Sintilimab combined with FLOT regimen,Docetaxel#50mg/m2d1,iv infusion for 1 hour#,Oxaliplatin#80mg/m2d1#iv infusion for 2 hours#,Calcium,leucovate#200mg/m2d1#iv infusion# ,Fluorouracil#2600mg/m2,intravenous drip for 24h# Every 14 days is one cycle# Sintilimab#200mg, d1#iv infusion Every 21 days is one cycle.
Study: NCT01985074

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Case-management intervention
Description: The participants in the intervention group receives a nurse-managed case-management intervention that is regularly delivered by telephone or, when necessary, in person.
Study: NCT02016313

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: physiotherapy

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: physiotherapy
Study: NCT02933021

Intervention type: OTHER
Intervention: Blood sample taken

Intervention type: OTHER
Intervention: Answering a lifestyle questionnaire

Intervention type: OTHER
Intervention: Follow-up phone call from researcher (two years after first visit)
Description: To enquire about status of participants monoclonal gammopathy of unknown significance, and whether there has been progression to multiple myeloma.
Study: NCT03621358

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control gummy with free flavour (without encapsulating)
Description: 12 g/day (3 gummies)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental gummy with 50% free/50% encapsulated flavour
Description: 12 g/day (3 gummies)
Study: NCT00432068

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Octreotide pamoate
Study: NCT00700193

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Influenza Virus Vaccine
Description: 2 dose vaccine regimen: 2 X 0.25mL vaccinations 30 days apart and a booster vaccination was administered 12 months after the first dose

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Influenza Virus Vaccine
Description: 2 dose vaccine regimen: 2 X 0.50mL vaccinations 30 days apart and a booster vaccination was administered 12 months after the first dose
Study: NCT04865289

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenvatinib
Description: Lenvatinib 4 mg or 10 mg capsules at a total daily dose of 20 mg taken by mouth once per day.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab 200 mg IV infusion given on Day 1 of each cycle.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: Paclitaxel 175 mg/m\^2 IV infusion given on Day 1 of each cycle.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: Carboplatin 10 mg/mL IV infusion at a total dose of are-under-the-curve (AUC) 6 (per Calvert's formula) given on Day 1 of each cycle.
Study: NCT01494324

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CT guided percutaneous ablation
Description: Depending on tumor size and location, we will direct a core biopsy needle in the ablated tumor using post-ablation dynamic Liver CT guidance, preferably including liver triphasic examination. The obtained tissue will be detached, collected and submitted to our molecular cytology laboratory. All specimens will be submitted fresh to our molecular cytology laboratory for immediate analysis in order to classify them as viable tumor (V) or apoptotic cells/coagulation necrosis (CN). CT will be performed within 24 hours of the ablation to demonstrate the ablation defect, representing the area of coagulation necrosis. This CT will be used for targeting the ablated tumor for biopsy. All patients will undergo CT again, approximately within 4-8 weeks (+/- 2 weeks) of percutaneous ablation to evaluate for CN in the target tumor or any sign of residual tissue enhancement, representing incomplete treatment.
Study: NCT00577694

Intervention type: DRUG
Group type: OTHER
Intervention: clofarabine
Description: Intravenous, 20mg/m2, Days 1, 2, 3, 4 and 5; 2 cycles

Intervention type: DRUG
Group type: OTHER
Intervention: gemtuzumab ozogamicin
Description: Intravenous, 3mg/m2, Day 1, one cycle
Study: NCT03621358

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental gummy with 100% encapsulated flavour
Description: 12 g/day (3 gummies)
Study: NCT02875158

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Cyclophotocoagulation protocol
Description: * Intravenous route is installed~* Retrobulbar anaesthesia : 50% xylocaine (2%) + 50% bupivicaine~* Parameters set for laser treatment (1250mW-4seconds or 2000mW-2 seconds depending on the assigned group)~* Pars plana measurement using transillumination (if needed)~* Laser treatment applied approximately 1mm post to limbus~* Dexamethasone 0,5 mg subconjunctival injection~* Post-op regimen: Prednisolone 1% qid x 4 weeks, Atropine 1% bid x 2 weeks + Erythromycin ointment + patch x 6h
Study: NCT03949868

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: High Mindfulness
Description: Those in the high mindfulness group will also receive questions about their memory performance over the past 30 minutes in both the morning and evening for six days. In order to emphasize the variability in pain, participants will receive these text messages on a variable schedule. In addition, they will sent instructions every morning to pay attention to variability in their memory performance throughout the day and asked to report on how their memory performance is changing over time as a part of each text message prompt.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Low Mindfulness
Description: Those in the low mindfulness group, who will receive receive two text messages per day (one at at 9am and one at 8pm) for six days, each prompting them to write about the activity they are currently engaged in. They will also be prompted with the 9am text to report on their memory performance over the past 30 minutes.
Study: NCT03936270

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letrozole 2.5mg
Description: Letrozole will be supplied as a 2.5 mg film-coated tablet. It must be taken at the recommended dose of 2.5 mg once daily.
Study: NCT03402269

Intervention type: OTHER
Intervention: Clavicle fracture injury- observation
Description: The study is an observational study with assessments at 1 month, 3 months, 6 months and 1 year following injury. Assessments include range of motion, strength, patient reported outcomes and radiographic healing
Study: NCT02875158

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cyclophotocoagulation protocol
Description: * Intravenous route is installed~* Retrobulbar anaesthesia : 50% xylocaine (2%) + 50% bupivicaine~* Parameters set for laser treatment (1250mW-4seconds or 2000mW-2 seconds depending on the assigned group)~* Pars plana measurement using transillumination (if needed)~* Laser treatment applied approximately 1mm post to limbus~* Dexamethasone 0,5 mg subconjunctival injection~* Post-op regimen: Prednisolone 1% qid x 4 weeks, Atropine 1% bid x 2 weeks + Erythromycin ointment + patch x 6h

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional cyclophotocoagulation
Description: 1250 mW for 4 seconds.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Modified cyclophotocoagulation
Description: 2000 mW for 2 seconds.
Study: NCT02122406

Intervention type: OTHER
Intervention: Hospital Anxiety and Depression Scale (HADS) questionnaire
Description: Patients filled in the Hospital Anxiety and Depression Scale (HADS) questionnaire
Study: NCT00073242

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leptin
Description: leptin administration

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dietary modification
Description: Subjects lose 10% of body weight via dietary restriction

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dietary modification
Description: Subjects lose 10% of body weight via dietary restriction

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: T3 repletion
Description: administer T3
Study: NCT04868136

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: 30 minutes of exercise at 80% of maximum predicted heart rate performed on an indoor stationary bicycle. Exercise was preceded by 10 min of gradually increasing cycling intensity in one of two exercise trials
Study: NCT03726281

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab 240 mg, IV
Study: NCT00826449

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dasatinib
Description: Starting dose of 70 mg by mouth daily for 21 day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib
Description: 150 mg by mouth daily every 21 day cycle.
Study: NCT00334100

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Exercise
Description: Treadmill exercise
Study: NCT03768726

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ziprasidone
Description: All investigational products will be provided by Pfizer and will include oral ziprasidone capsules of 20, 40, 60, and 80 mg strength. Matching placebo capsules will also be supplied for the initial 1-14 day dose transition period. During the transition period all subjects will receive both active ziprasidone and placebo capsules. The placebo capsules are used to maintain the blind to the treatment assignment of the subjects in A1281198 . All medication will be packaged in childproof blister cards with columns for AM and for PM capsules. During the dose transition period (Weeks 1-2, Days 1-14), subjects will receive a study drug blister card for each week of transition dosing. Subjects weighing greater than 45 kg will receive 2 weeks of transition medication, while subjects weighing less than 45 kg will receive 1 week of transition medication.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: All investigational products will be provided by Pfizer and will include oral ziprasidone capsules of 20, 40, 60, and 80 mg strength. Matching placebo capsules will also be supplied for the initial 1-14 day dose transition period. During the transition period all subjects will receive both active ziprasidone and placebo capsules. The placebo capsules are used to maintain the blind to the treatment assignment of the subjects in A1281198 . All medication will be packaged in childproof blister cards with columns for AM and for PM capsules. During the dose transition period (Weeks 1-2, Days 1-14), subjects will receive a study drug blister card for each week of transition dosing. Subjects weighing greater than 45 kg will receive 2 weeks of transition medication, while subjects weighing less than 45 kg will receive 1 week of transition medication.
Study: NCT00444093

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Opii normata treatment
Description: After beginning of diarrhea grade 1:~5 drops tincture of opium three times a day~After beginning of diarrhea grade 2:~Intensive therapy with 15 drops tincture of opium three times a day.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Loperamid Treatment
Description: All patients who receive as a result of randomisation loperamide~After beginning of diarrhea grade 1:~Initial 4mg and 2mg after any unformed stool. The maximum dose amounts to16mg per day.~After beginning of diarrhea grade 2:~Intensive therapy with 2mg loperamide every 2 h. The maximum dose amounts to 16mg per day.
Study: NCT00324766

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: levosimendan
Description: 1 h infusion, 0.2 microgs/kg/min, 24 h infusion,0.1 microgs/kg/min

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo,
Description: 24 h, infusion
Study: NCT03544996

Intervention type: COMBINATION_PRODUCT
Intervention: TD Insulin
Description: Human Insulin USP formulated in a solution capable of transdermal delivery.
Study: NCT01725776

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inhaled milrinone 5 mg
Description: Inhaled milrinone 5 mg (as for the injectable solution)
Study: NCT03972267

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Free gingival graft
Description: Free Gingival Graft removal from the palate donor area for socket preservation

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Free gingival graft
Description: Free Gingival Graft removal from the palate donor area for socket preservation

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Enamel Matrix Derivate
Description: EMD in contact with the palate wound for 5 min. After this time, palatal area will be covered with an individualized acetate plate which will stay in position for 2 hours after the procedure
Study: NCT05219461

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Single dose of rhEGF 10mcg/ml or placebo
Description: 6 subjects will be assigned to rhEGF 10mcg/ml eye drop and 2 subjects will be assigned to placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Single dose of rhEGF 50mcg/ml or placebo
Description: 6 subjects will be assigned to rhEGF 50mcg/ml eye drop and 2 subjects will be assigned to placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Single dose of rhEGF 100mcg/ml or placebo
Description: 6 subjects will be assigned to rhEGF 100mcg/ml eye drop and 2 subjects will be assigned to placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Multiple dose of rhEGF 10mcg/ml or placebo
Description: 6 subjects will be assigned to rhEGF 10mcg/ml eye drop and 2 subjects will be assigned to placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Multiple dose of rhEGF 50mcg/ml or placebo
Description: 6 subjects will be assigned to rhEGF 50mcg/ml eye drop and 2 subjects will be assigned to placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Multiple dose of rhEGF 100mcg/ml or placebo
Description: 6 subjects will be assigned to rhEGF 100mcg/ml eye drop and 2 subjects will be assigned to placebo
Study: NCT01218113

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1 or 3 doses according to protocol schedule
Study: NCT02027883

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Nominal T shock setting
Description: Nominal Parameter Set 1 Programming Values for EnTrust

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Educated T shock setting
Description: Experimental Parameter Set 2 Programming Values
Study: NCT03613844

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DHA
Description: DHA supplementation
Study: NCT02141113

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Guanfacine Hydrocholride
Description: 1. mg Guanfacine Hydrochloride (orally)~2. mg Guanfacine Hydrochloride (orally)~3. mg Guanfacine Hydrochloride (orally)~4. mg Guanfacine Hydrochloride (orally)~5. mg Guanfacine Hydrochloride (orally)~6. mg Guanfacine Hydrochloride (orally)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Guanfacine Hydrocholride
Description: 1. mg Guanfacine Hydrochloride (orally)~2. mg Guanfacine Hydrochloride (orally)~3. mg Guanfacine Hydrochloride (orally)~4. mg Guanfacine Hydrochloride (orally)~5. mg Guanfacine Hydrochloride (orally)~6. mg Guanfacine Hydrochloride (orally)
Study: NCT01545024

Intervention type: DRUG
Intervention: Sitagliptin, 50 mg once per day per os
Description: Before and one year after treatment with DPP-IV inhibitor in diabetic patients with AND.
Study: NCT00833807

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab-Paclitaxel (Abraxane)
Description: Day 1 of Cycles 1-6, Starting Dose of 130 mg/m2 received through arterial catheter over 30 minutes. Cycle is 21 Days.~Day 1 of Cycle 7+, Dose received through catheter in vein over 30 minutes. Cycle is 21 Days.
Study: NCT03029897

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: My eReport France
Description: patients are educated to the use of My eReport France application
Study: NCT03734562

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ablation
Description: Substrate-based radiofrequency catheter ablation

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Antiarrhythmic drug
Description: Amiodarone or sotalol therapy
Study: NCT01022151

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo [group P]
Description: receive intravenous injection of 0.2 mL/kg of saline 0.9%L \[group P\]. All study solutions were injected within 1 min at T0 after discontinuation of sevoflurane. No stimulation was applied to patients during this period.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0.2 mL/kg of aminophylline 10 mg/mL [group A2]
Description: receive intravenous injection of 0.2 mL/kg of aminophylline 10 mg/mL \[group A2\]. All study solutions were injected within 1 min at T0 after discontinuation of sevoflurane. No stimulation was applied to patients during this period.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0.2 mL/kg of aminophylline 15 mg/mL [group A3]
Description: receive intravenous injection of 0.2 mL/kg of aminophylline 15 mg/mL \[group A3\]. All study solutions were injected within 1 min at T0 after discontinuation of sevoflurane. No stimulation was applied to patients during this period.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0.2 mL/kg of aminophylline 20 mg/mL [group A4]
Description: receive intravenous injection of 0.2 mL/kg of aminophylline 20 mg/mL \[group A4\]. All study solutions were injected within 1 min at T0 after discontinuation of sevoflurane. No stimulation was applied to patients during this period.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0.2 mL/kg of aminophylline 25 mg/mL [group A5]
Description: receive intravenous injection of 0.2 mL/kg of aminophylline 25 mg/mL \[group A5\]. All study solutions were injected within 1 min at T0 after discontinuation of sevoflurane. No stimulation was applied to patients during this period.
Study: NCT00673153

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemtuzumab ozogamicin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vorinostat
Description: Given orally

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT00879892

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: xenon
Description: Gas, 24 hour inhalation, en tidal target concentration 40%

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Hypothermia
Description: 24 hour, target core temperature 33

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Hypothermia
Description: 24 hour, target core temperature 33
Study: NCT01323465

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sativex and rifampicin
Description: Single dose of 4 sprays Sativex on Day 1, Rifampicin 2 x 300 mg capsules on Days 2-10, Sativex dose of 4 sprays and rifampicin 2 x 300 mg capsules on Day 11.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sativex and rifampicin
Description: Rifampicin 2 x 300 mg capsules on Days 1-9, Sativex x 4 sprays and rifampicin 2 x 300 mg capsules on Day 10, Single dose of Sativex 4 sprays on Day 18.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sativex and ketoconazole
Description: Single dose of 4 sprays Sativex on Day 1, ketoconazole 2 x 200 mg tablets on Days 2-5, Sativex x 4 sprays and ketoconazole 2 x 200mg on Day 6.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sativex and ketoconazole
Description: Ketoconazole 2 x 200 mg tablets on Days 1-4, Sativex x 4 sprays and ketoconazole 2 x 200 mg tablets on Day 5, Single dose of 4 sprays Sativex on Day 9.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sativex and omeprazole
Description: Single dose of 4 sprays of Sativex on Day 1 Omeprazole 2 x 20 mg on Days 2-6. Sativex x 4 sprays and omeprazole 2 x 20 mg on Day 9.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sativex and omeprazole
Description: Omeprazole 2 x 20 mg on Days 1-5, Sativex x 4 sprays and omeprazole 2 x 20 mg on Day 6, Single dose of 4 sprays Sativex on Day 9.